Latest Market News

RAS Technology Holdings Limited reported a robust 31% increase in revenue to A$21.3 million for FY25, alongside its first net profit after tax since listing, driven by strategic acquisitions and global expansion.

Sequoia Financial Group reported steady revenue but a sharp profit decline in FY25, driven by divestments and goodwill impairment. The company simplified its business structure and strengthened governance while maintaining dividend payouts.

Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.

Comms Group Limited reported a steady 2% revenue increase to $56.6 million in FY25, hitting the top end of guidance despite margin pressures from global expansion investments. The recent TasmaNet acquisition is on track to drive future growth.

De.mem Limited reported a 19.7% increase in revenue to $13.96 million for the half-year ended June 2025, alongside a 42% reduction in net loss and its first positive adjusted EBITDA in years. Strategic acquisitions and expansion into Asian domestic markets underpin the company’s improving financial health.

Comms Group delivered FY25 results at the upper end of guidance, boosted by record new sales and the acquisition of TasmaNet. The company sets sights on accelerated growth and integration benefits in FY26.

archTIS has successfully raised A$8.7 million through a fully underwritten placement and institutional entitlement offer, backing its strategic acquisition of Spirion LLC assets and expansion plans. A retail entitlement offer is set to follow, aiming to raise an additional A$11.7 million.

Beam Communications reports a pivotal FY25 marked by the divestment of its Zoleo joint venture, unlocking significant capital and delivering improved margins despite a statutory revenue decline. The company projects positive operating cash flow and growth in FY26.

Westgold Resources has declared a strong final dividend for FY25 and unveiled an enhanced dividend policy alongside a significant share buy-back program, signaling robust confidence in its growth and cash flow outlook.

Rhythm Biosciences has formalised a strategic co-marketing partnership with the Know Your Lemons Foundation to promote its geneType Breast Cancer Risk Assessment Test, expanding access to early detection tools for women in the US and Australia.

Starpharma has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year, reinforcing its commitment to advancing dendrimer technology and biotechnology innovation in Australia.

Hartshead Resources has voluntarily suspended trading on the ASX pending a significant announcement about a well carry agreement linked to its P2607 Licence. The suspension is set to last until the announcement or early September.